Mechanisms of 17β-estradiol on the production of ET-1 in ovariectomized rats

Life Sciences

Volumn 73, Issue 21, 2003, Pages 2665-2674

  Tan, Zhi ^a   Wang, Ting Huai ^a   Yang, Dang ^a   Fu, Xaio Dong ^a   Pan, Jing Yun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Atherosclerosis; Endothelin converting enzyme; Endothelin 1; Estrogen; Vascular smooth muscle cells

Indexed keywords

ENDOTHELIN 1 DERIVATIVE; ESTRADIOL; MESSENGER RNA; ASPARTIC PROTEINASE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN-CONVERTING ENZYME 1; METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG INHIBITION; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HORMONAL REGULATION; NONHUMAN; OVARIECTOMY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RANDOMIZATION; RAT; RECEPTOR DOWN REGULATION; SHAM FEEDING; SPECIES COMPARISON; ANIMAL; BLOOD; DRUG EFFECT; GENETICS; IN VITRO STUDY; METABOLISM; MUSCLE CONTRACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; ASPARTIC ENDOPEPTIDASES; ENDOTHELIN-1; ESTRADIOL; FEMALE; INJECTIONS, SUBCUTANEOUS; METALLOENDOPEPTIDASES; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0141560330     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00605-2     Document Type: Article

References (30)

1. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S., Clarkson T.B. Inhibition of coronary artery atherosclerosis by 17beta-estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 10(6):1990;1051-1057.
2. Akishita M., Kozaki K., Eto M., Yoshizumi M., Ishikawa M., Toba K., Orimo H., Ouchi Y. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochemical Biophysical Research Communications. 251(1):1998;17-21.
3. Barton M., Cosentino F., Brsndes R.P., Moreau P., Shaw S., Luscher T.F. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hyptertension. 30(4):1997;817-824.
4. Barton M., Shaw S., d'Uscio L.V., Moreau P., Luscher T.F. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochemical Biophysical Research Communications. 238(3):1997;861-865.
5. Bayard F., Elhage R., Rami J., Maret A., Arnal J.F. Effect of estrogens on arterial physiology and mechanisms of their atheroprotective action in the animal. Diabetes Metabolism. 25(Suppl. 3):1999;46-52.
6. Best P.J., Berger P.B., Miller V.M., Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Annals of Internal Medicine. 128(4):1998;285-288.
7. Bilsel A.S., Moini H., Tetik E., Aksungar F., Kaynak B., Ozer A. 17Beta-estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovascular Research. 46(3):2000;579-584.
8. Chiou W.J., Shiosaki K., Tasker A.S., Wu-Wong J.R. Characterization of two endothelin converting enzymes and their preference for big endothelin-1 and -2 as substrates. Life Sciences. 54(21):1994;1613-1619.
9. Clarkson T.B., Adams M.R., Williams J.K., Wagner J.D. Douglas P.S. Cardiovascular Health and Disease in Women. 1993;283-302 Saunders, Philadelphia.
10. Dashwood M.R., Tsui J.C. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis. 160(2):2002;297-304.
11. David F.L., Carvalno M.H.C., Cobra A.L.N., Nigro D., Fortes Z.B., Reboucas N.A., Tostes R.C.A. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension. 38(Part 2):2001;692-696.
12. Dubey R.K., Jackson E.K., Keller P.J., Imthurn B., Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension. 37(Part 2):2001;640-644.
13. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Re-search Group. Journal of American Medical Association. 280(7):1998;605-613.
14. Inoue A., Yanagisawa M., Takuwa Y., Mitsui Y., Kobayashi M., Masaki T. The human preproendothelin-1 gene complete nucleotide sequence and regulation of expression. Journal of Biological Chemistry. 264(25):1989;14954-14959.
15. Levin E.R. Endothelins. New England Journal of Medicine. 333(6):1995;356-363.
16. Mikkola T.S., Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovascular Research. 53(3):2002;605-619.
17. Miyauchi T., Yanagisawa M., Iida K., Ajisaka R., Suzuki N., Fujino M., Goto K., Masaki T., Sugishita Y. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. American Heart Journal. 123(4 Part 1):1992;1092-1103.
18. Morey A.K., Razandi M., Pedram A., Hu R.M., Prins B.A., Levin E.R. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochemical Journal. 330(Part 3):1998;1097-1105.
19. Mosca L., Manson J.E., Sutherland S.E., Langer R.D., Manolio T., Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 96(7):1997;2468-2482.
20. Mosca L., Collins P., Herrington D.M., Mendelsohn M.E., Pasternak R.C., Robertson R.M., Schenck-Gustafsson K., Smith S.C. Jr., Taubert K.A., Wenger N.K. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 104(4):2001;499-503.
21. Polderman K.H., Stehouwer C.D., van Kamp G.J., Schalkwijk C.G., Gooren L.J. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism. 49(5):2000;648-650.
22. Polderman K.H., Stehouwer C.D., van Kamp G.J., Dekker G.A., Verheugt F.W., Gooren L.J. Influence of sex hormone on plasma endothelin levels. Annals of Internal Medicine. 118(6):1993;429-432.
23. Rizzi A., Calo G., Battistini B., Regoli D. Contractile activity of endothelins and their precursors in human umbilical artery and vein: identification of distinct endothelin-converting enzyme activities. Journal of Cardiovascular Pharmacology. 31(Suppl. 1):1998;S58-S61.
24. Schweizer A., Valdenaire O., Nelbock P., Deuschle U., Dumas Milne Edwards J.B., Stumpf J.G., Loffler B.M. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochemical Journal. 328(Part 3):1997;871-877.
25. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prevent Medicine. 20(1):1991;47-63.
26. Tolbert T., Oparil S. Cardiovascular effects of estrogen. American Journal of Hypertens. 14(6 Part 2):2001;186S-193S.
27. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., de Wit D., Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78(3):1994;473-485.
28. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332(6163):1988;411-415.
29. Ylikorkala O., Orpana A., Puolakka J., Pyorala T., Viinikka L. Postmenopausal hormone replacement decreases plasma levels of ET-1. Journal of Clinical Endocrinology and Metabolism. 80(11):1995;3384-3387.
30. Zeiher A.M., Goebel H., Schilchinger V., Ihiling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 91(4):1995;941-947.